CClinicalTrials.gg
Enrolling by invitationNCT07665502Updated Jul 28, 2026

Pre-Pilot (R61) WINGS+++: mHealth to Improve MOUD Uptake in Women Experiencing Intimate Partner Violence and PTSD

An interventional study of Pre-Pilot WINGS++++ in Opioid-Related Disorders, Substance-Related Disorders and Intimate Partner Violence (IPV), sponsored by Dawn A. Goddard-Eckrich. Enrolling by invitation at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Dawn A. Goddard-Eckrich · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The goal of this pre-pilot for the clinical trial is to develop a mobile health (mHealth) program called WINGS+++ can help women with opioid use disorder or other substance use disorders who have experienced intimate partner violence. The pre-pilot study will take place in Orange County, New York with n=7 women. .

The main questions it aims to answer are:

  1. Does WINGS+++ lower non-prescription opioid and other drug use in women?
  2. Does WINGS+++ help connect women to treatment for substance use, intimate partner violence, and post-traumatic stress disorder (PTSD)?

Researchers will compare WINGS+++ to standard care to see if WINGS+++ works better to lower drug use and link women to helpful services.

WINGS+++ is a 3-session program on a mobile device that:

  • Screens for intimate partner violence, PTSD, and substance use
  • Offers brief support and referrals based on each woman's needs and preferences
  • Connects women to a peer navigator who helps link them to services

Participants will:

  • Take part in only the WINGS+++ program for the pre-pilot
  • Answer survey questions about drug use, intimate partner violence, and PTSD symptoms
  • Provide biological samples (such as urine or hair) to check for drug use
  • Share information about the services they have used
Read the detailed description

The goal of this pre-pilot for the clinical trial is to develop a mobile health (mHealth) program called WINGS+++ that can help women with opioid use disorder or other substance use disorders who have experienced intimate partner violence. The pre-pilot study will take place in Orange County, New York with n=7 women.

WINGS+++ is delivered across 3 sessions on a mobile device and combines three components into a single program: a tool that screens for physical, sexual, and emotional abuse and provides brief support and safety planning; a tool that identifies trauma-related (PTSD) symptoms and offers brief education and coping strategies; and a tool that screens for substance use concerns and helps connect women to appropriate treatment. The program also includes peer navigators, trained individuals with lived experience of substance use, intimate partner violence, or both who help connect participants to services based on their screening results and preferences.

This pre-pilot is a single-arm study in which all participants receive WINGS+++. The main goals are to assess whether the program and study procedures are feasible, acceptable to participants, and safe. Feasibility will be measured through factors such as recruitment, retention, session completion, and successful connection to referred services. Acceptability will be assessed through participant feedback, including interviews about their experience. Safety will be monitored by tracking any adverse events. Findings will be used to refine the program before later phases of the study.

02

Conditions studied

  • Opioid-Related Disorders
  • Substance-Related Disorders
  • Intimate Partner Violence (IPV)
  • Stress Disorders, Post-Traumatic
  • Domestic Violence
  • Medication for Opioid Use Disorder (MOUD)
  • Post Traumatic Stress Disorder PTSD
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Identify as a woman (cisgender or transgender)
  • Aged 18 or older
  • Report use of non-prescribed opioids in the past 30 days
  • Score positive for risk of opioid use disorder or other substance use disorder on the Drug Abuse Screening Test (DAST) with a cut-off score of 6 or higher
  • Report experiencing any severe psychological abuse or any physical or sexual abuse by a female or male intimate partner in the past year.

Exclusion criteria

Exclusion Criteria:

  • Evidence of significant psychiatric or cognitive impairment that would limit effective participation, as confirmed during informed consent;
  • Inability to speak and understand English sufficiently to participate in assessments or intervention sessions.
04

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (estimated)

Study arms

  • Experimental
    Pre-Pilot WINGS+++ Intervention

    Participants will receive the WINGS+++ 3-session mHealth intervention with peer navigation delivered over a 30-day period. Session 1 focuses on OUD/SUD screening, brief intervention, and referral to treatment (SBIRT) and includes a 40-minute mHealth tool plus a 20-minute peer navigator check-in. Session 2 focuses on IPV SBIRT and includes a 60-minute mHealth tool plus 20 minutes of peer navigation. Session 3 focuses on PTSD SBIRT and closing activities and includes a 60-minute mHealth tool plus 20 minutes of peer navigation. WINGS+++ mHealth sessions may be delivered using tablets at study sites or participant smartphones. Participants will also receive peer navigation from Community Health Advocates with lived experience of substance use disorder and/or intimate partner violence.

    Behavioral: Pre-Pilot WINGS++++

Interventions

  • BehavioralPre-Pilot WINGS++++

    Pre-Pilot WINGS+++ Intervention (3 sessions) After completing the baseline survey, they will participate in the three-session WINGS+++ program using a tablet, computer, or smartphone. The sessions include educational videos, interactive exercises, safety planning tools, and activities designed to address intimate partner violence, trauma symptoms, and substance use. Work with a Community Health Advocate (Peer Navigator) who will help set goals and connect you to services such as MOUD treatment, harm reduction services, mental health services, and intimate partner violence services.

05

What researchers measure

Primary outcomes

  1. Mean Score on the WINGS+++ Satisfaction Scale - Pre-Pilot Phase

    Acceptability will be measured using a study-specific 12-item satisfaction scale administered after the intervention. Each item is rated on a 4-point Likert scale from 1 (very unsatisfied) to 4 (very satisfied). A mean score is calculated across the 12 items, ranging from 1 to 4. Higher scores indicate greater acceptability.

    Time frame: 1 month post-intervention

Other outcomes

  1. Percentage of Participants Who Complete All 3 WINGS+++ Sessions - Pre-Pilot Phase

    Feasibility of intervention delivery will be assessed as the percentage of participants who complete all 3 WINGS+++ sessions. Higher percentages indicate greater feasibility.

    Time frame: 30 days per participant

  2. Number of Participants Who Complete the Post-Intervention Focus Group - Pre-Pilot Phase

    Participant feedback to refine the intervention will be gathered through a post-intervention focus group workshop. Reported as the number of participants who complete the focus group.

    Time frame: 1 month post intervention

  3. Number of Key Stakeholders Who Complete the Survey and Interview - Group Pre-Pilot Phase

    Key stakeholder input to inform pre-pilot refinement and pilot phase design will be gathered using the WINGS+++ Coalition and Key Stakeholder Survey (adapted from the HEALing Communities Study Community Coalition and Key Stakeholder Survey) and a qualitative interview. Reported as the number of stakeholders who complete both the survey and interview.

    Time frame: 1 months

  4. Mean Stakeholder Rating of WINGS+++ Acceptability and Feasibility Pre-Pilot

    Key stakeholder and coalition input to inform pilot phase design will be assessed using the WINGS+++ Coalition and Key Stakeholder Survey, adapted from the HEALing Communities Study Community Coalition and Key Stakeholder Survey. Stakeholders rate items on 5-point Likert scales (e.g., 1 = Strongly Disagree to 5 = Strongly Agree; 1 = Very Dissatisfied to 5 = Very Satisfied), with mean scores ranging from 1 to 5. Higher scores indicate greater readiness, satisfaction, and support for implementing WINGS+++. Findings will be used to refine the intervention and study protocols for the subsequent pilot phase.

    Time frame: 1 months

06

Study locations

2 sites
  • Columbia University School of Social Work
    New York, New York 10027, United States
  • Cornerstone
    Newburgh, New York 12550, United States
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07665502
Lead sponsor
Dawn A. Goddard-Eckrich
Collaborators
National Institute on Drug Abuse (NIDA), City University of New York, University of Pennsylvania
Responsible party
Dawn A. Goddard-Eckrich (Associate Director, Columbia University) — Sponsor-investigator
First posted
Jun 24, 2026
Start date
Apr 21, 2026
Primary completion
Aug 27, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jul 28, 2026

Study contacts

Louisa Gilbert, PhD
study chair · Columbia University
Nabila El-Bassel, PhD
study chair · Columbia University
Dawn A Goddard-Eckrich, EdD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion